IQ-AI Limited IQ-AI Prepares for Phase I Clinical Trial Launch (0182W)
December 17 2021 - 2:37AM
UK Regulatory
TIDMIQAI
RNS Number : 0182W
IQ-AI Limited
17 December 2021
17 December 2021
IQ-AI LIMITED
("IQ-AI" or the "Company")
IQ-AI Prepares for Phase I Clinical Trial Launch
IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) ,
IQ-AI has been working with the clinical team at the Medical
College of Wisconsin (MCW) to qualify a new supplier for
encapsulating the drug candidate. The Company is pleased to
announce that a supplier has been contracted and the production of
the capsules is now underway. IQ-AI anticipates the trial will
commence in February 2022.
While the qualification of a new supplier imposed a delay to the
start of the trial, a robust source of supply is now ready to
provide an efficient and continuous distribution of capsules to
enrolled patients for this Phase I as well as subsequent
trials.
"We appreciate everyone's efforts to secure an alternative
encapsulation supplier for oral GaM and now await the start of this
clinical trial," said Trevor Brown, CEO of IQ-AI.
The Directors of the Company accept responsibility for the
contents of this announcement.
- ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms
part of retained EU law (as defined in the European Union
(Withdrawal) Act 2018).
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Imaging Biometrics, LLC (IB), develops and provides visualisation
and analytical solutions that enable clinicians to better diagnose
and treat disease with greater confidence. Through close
collaboration with top researchers and clinicians, sophisticated
advancements are translated into platform-independent and automated
software plug-ins which can extend the base functionality of
workstations, imaging systems, PACS, or medical viewers. By design,
IB's advanced visualisation software seamlessly integrates into
routine workflows. For more information about Imaging Biometrics,
visit the company's website at www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDUBOBRANUUARA
(END) Dow Jones Newswires
December 17, 2021 02:37 ET (07:37 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2023 to Apr 2024